Peptide Based Gastrointestinal Disorders Therapeutics Market Estimated to Record Highest CAGR by 2017 to 2022 | Key Players are Shire plc, Astellas Pharma Inc., Allergan plc, etc.

In order to dissert the market scenario prevailing across the peptide based gastrointestinal disorders therapeutics market sector, Fact.MR has evenly presented a comprehensive analysis report on peptide based gastrointestinal disorders therapeutics market to its extensive online repository. With all vital market facets enclosed into this single assessment, readers can learn about different market drivers, opportunities and trends which are likely to influence the overall market space for the peptide based gastrointestinal disorders therapeutics market in the coming years. In addition, factors such as market size, Y-o-Y growth and revenue share are investigated so as to make this research highly authentic and reliable.

Get Free Sample Report from Here - https://www.factmr.com/connectus/sample?flag=S&rep_id=190

Medical research institutes as well as leading companies in the pharmaceutical industry are ramping up their efforts toward development of profound therapeutic drugs for treating gastrointestinal disorders. This FactMR report analyzes the expansion of global peptide based gastrointestinal disorders therapeutics market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.

Pharmaceutical companies are increasingly collaborating with medical institutes and research centers in order to ramp up R&D pipelines of peptide drugs. This is expected to influence the growth of the global peptide based gastrointestinal disorders therapeutics market over the next couple of years. Rising prevalence of metabolic diseases and gastrointestinal disorders pertaining to the digestive system is prompting medical practitioners to utilize new therapeutics including peptides. In the near future, application of peptides is also expected to increase in other therapeutic areas as well. Moreover, technological advancement in peptide synthesis which include hybrid combination of liquid and solid synthesis and high-throughput approaches is expected to play a crucial role in development of more effective peptide based therapeutic drugs for treating gastrointestinal disorders. Such developments in the peptide therapeutics is also giving new hope to patients seeking affordable and effect therapeutic treatments. In addition, manufacturers are actively focusing on improving peptide properties, such as half-life and stability to address the various unmet medical needs. According to the latest report published by Fact.MR, the global peptide based gastrointestinal disorders therapeutics market is set to reflect a double-digit CAGR between 2017 and 2022, to surpass a valuation of US$ 600 Mn.

Peptide is a biologically, naturally or artificially constituted form of amino acid monomers. Peptides can be utilized for treating various gastrointestinal disorders that mostly effect parts of the digestive system such as the gastrointestinal tract, large intestine, small intestine, stomach, esophagus, and rectum. Peptides are considered as an effective therapeutic agent for treating gastrointestinal diseases. Owing to their impressive preclinical results, an array of new peptide based gastrointestinal disorder therapeutics are expected to enter the market soon.

In terms of revenue, North America is expected to hold the dominant share of the global peptide based gastrointestinal disorders therapeutics market in 2017 and beyond. Factors such growing patient awareness and rapid adoption of peptide based therapeutics for treating various diseases are expected to support the growth of the market in the region.  During the forecast period, the market in the region is projected to surge at a robust CAGR of 13.9%.

On the basis of drugs, the linaclotide segment is expected to retain its dominant position over 2022. Currently, the segment accounts for more than two-third share of the market in terms of revenue. Towards the end of the forecast period, the linaclotide segment is estimated to reach a market valuation in excess of US$ 466 Mn.

Competition Tracking

Shire plc, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Allergan plc, Accredo Health Group, Inc., are the key market players profiled in the FactMR’s report. A majority of these companies are channelizing investment in further expansion of their product portfolio. This, in turn, is anticipated to result in introduction of more efficacious peptide based therapeutic drugs for curing gastrointestinal ailments.

Table of Contents

Global Peptide Based Gastrointestinal Disorders Therapeutics Market - Executive Summary
Global Peptide Based Gastrointestinal Disorders Therapeutics Market Overview
2.1. Introduction

       2.1.1. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Taxonomy

       2.1.2. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Definition

2.2. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022

       2.2.1. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Y-o-Y Growth

2.3. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Dynamics

2.4. Regulations

2.5. Supply Chain

Continued…………………….

Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=190

Contact Us
FactMR
11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at: https://insiderstribune.com

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.